Autor: "Szydlo DW" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: How a menu of adherence support strategies facilitated high adherence to HIV prevention products among adolescent girls and young women in sub-Saharan Africa: a mixed methods analysis.
Autorzy:: Roberts ST; Women's Global Health Imperative, RTI International, Berkeley, California, USA.
Mancuso N; Women's Global Health Imperative, RTI International, Atlanta, Georgia, USA.
Williams K; Applied Public Health Research Center, RTI International, Research Triangle Park, North Carolina, USA.
Nabunya HK; Makerere University-Johns Hopkins University Research Collaboration, Kampala, Uganda.
Mposula H; Wits Reproductive Health and HIV Institute, Johannesburg, South Africa.
Mugocha C; University of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe.
Mvinjelwa P; Desmond Tutu HIV Centre, Cape Town, South Africa.
Garcia M; FHI 360, Durham, North Carolina, USA.
Szydlo DW; Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Soto-Torres L; Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Ngure K; School of Public Health, Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya.; Department of Global Health, University of Washington, Seattle, Washington, USA.
Hosek S; Center for Dissemination and Implementation Science, University of Illinois Chicago, Chicago, Illinois, USA.; Pokaż więcej
Źródło:: Journal of the International AIDS Society [J Int AIDS Soc] 2023 Nov; Vol. 26 (11), pp. e26189.
Typ publikacji:: Randomized Controlled Trial; Journal Article
MeSH Terms:: Anti-HIV Agents*/therapeutic use
HIV Infections*/drug therapy
HIV Infections*/prevention & control
Pre-Exposure Prophylaxis*/methods
Adolescent ; Female ; Humans ; Counseling ; South Africa ; Zimbabwe ; Young Adult ; Cross-Over Studies

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: Baseline preferences for oral pre-exposure prophylaxis (PrEP) or dapivirine intravaginal ring for HIV prevention among adolescent girls and young women in South Africa, Uganda and Zimbabwe (MTN-034/IPM-045 study).
Autorzy:: Ngure K; School of Public Health, Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya.; Department of Global Health, University of Washington, Seattle, WA, United States of America.
Friedland BA; Population Council, Center for Biomedical Research, New York, NY, United States of America.
Szydlo DW; Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America.
Roberts ST; Women's Global Health Imperative (WGHI), RTI International, Berkeley, California, United States of America.
Garcia M; FHI 360, Durham, North Carolina, United States of America.
Levy L; FHI 360, Durham, North Carolina, United States of America.
Akello CA; Johns Hopkins University Research Collaboration, Makerere University, Kampala, Uganda.
Reddy K; Wits Reproductive Health and HIV Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Palanee-Phillips T; Wits Reproductive Health and HIV Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Macdonald P; Wits Reproductive Health and HIV Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Siziba B; University of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe.
Soto-Torres L; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
Hosek S; Department of Psychiatry, John Stroger Hospital of Cook County, Chicago, Illinois, United States of America.
Hillier SL; Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America.
Nair G; Centre for Medical Ethics and Law, Stellenbosch University, Stellenbosch, South Africa.
Celum C; Department of Global Health, University of Washington, Seattle, WA, United States of America.; Department of Medicine, University of Washington, Seattle, Washington, United States of America.; Department of Epidemiology University of Washington, Seattle, Washington, United States of America.
van der Straten A; Center for AIDS Prevention Studies, Dept of Medicine, University of California, San Francisco, San Francisco, California, United States of America.; ASTRA Consulting, Kensington, CA, United States of America.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2023 Jun 23; Vol. 18 (6), pp. e0287525. Date of Electronic Publication: 2023 Jun 23 (Print Publication: 2023).
Typ publikacji:: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
MeSH Terms:: Anti-HIV Agents*/therapeutic use
HIV Infections*/epidemiology
HIV Infections*/prevention & control
HIV Infections*/drug therapy
Pre-Exposure Prophylaxis*/methods
Adolescent ; Female ; Humans ; Pregnancy ; South Africa/epidemiology ; Uganda/epidemiology ; Zimbabwe/epidemiology ; Young Adult

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 3.

Tytuł:: HIV-1 drug resistance among individuals who seroconverted in the ASPIRE dapivirine ring trial.
Autorzy:: Parikh UM; Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Penrose KJ; Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Heaps AL; Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Halvas EK; Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Goetz BJ; Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Gordon KC; Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Hardesty R; Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Sethi R; Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Schwarzmann W; Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Szydlo DW; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Husnik MJ; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Chandran U; Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Palanee-Phillips T; Wits Reproductive Health and HIV Institute, Johannesburg, South Africa.
Baeten JM; Departments of Global Health, Medicine, Epidemiology, University of Washington, Seattle, Washington, USA.
Mellors JW; Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.; Pokaż więcej
Corporate Authors:: MTN-020 Study Team
Źródło:: Journal of the International AIDS Society [J Int AIDS Soc] 2021 Nov; Vol. 24 (11), pp. e25833.
Typ publikacji:: Clinical Trial, Phase III; Controlled Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
MeSH Terms:: Anti-HIV Agents*/pharmacology
Anti-HIV Agents*/therapeutic use
HIV Infections*/drug therapy
HIV Seropositivity*/drug therapy
HIV-1*/genetics
Drug Resistance, Viral/genetics ; HIV Reverse Transcriptase/genetics ; HIV Reverse Transcriptase/pharmacology ; HIV Reverse Transcriptase/therapeutic use ; Humans ; Mutation ; Pyrimidines ; Reverse Transcriptase Inhibitors/therapeutic use